QED Therapeutics doses first patients in infigratinib clinical trials
Category: #health  By Mateen Dalal  Date: 2020-03-14
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

QED Therapeutics doses first patients in infigratinib clinical trials
  • The trial monitors infigratinib in the post-surgery treatment of invasive urothelial carcinoma
     
  • Volunteers with a high risk of cancer recurrence after the surgery are being given FGFR3 genetic alterations

California headquartered pharmaceutical company- Bridge Bio Pharma Inc., has reportedly announced that QED Therapeutics has dosed patients in separate Phase 2 and Phase 3 clinical studies of infigratinib in the treatment of cancers.

Citing reliable sources, during the clinical trial, subjects having invasive urothelial cancer with susceptible FGFR3 genetic alterations who pose a higher risk of relapse following a surgical procedure are being given the treatment.

Reportedly, the Phase 3 PROOF 302 study which is sponsored by QED Therapeutics monitors infigratinib in the post-surgery treatment of invasive urothelial carcinoma – a type of cancer that usually develops in the urinary system.

Another investigator-initiated study is being carried out by Sameek Roychowdhury, M.D., Ph.D, Ohio State University Comprehensive Cancer Center, to understand the use of infigratinib towards the treatment of newly discovered and metastatic solid tumors with FGFR fusions or other alterations.

According to Sumanta Pal, M.D., professor of medical oncology and therapeutics research at City of Hope Comprehensive Cancer Facility and the PROOF 32 trial lead, many patients suffering from urothelial carcinoma witness a recurrence of cancer within two years of the surgery. These patents are likely to benefit from an oral, post-surgery medication that targets the FGFR3 alterations.  

Notably, the Phase 2 trial at the Ohio State University and other selected centers within the Oncology Research Information Exchange Network will study the efficiency of infigratinib in patients who are diagnosed with metastatic or advanced solid tumors that stand positive for FGFR1-3 gene fusions or other alterations.

Established in 2015, BridgeBio Pharma is a leading pharmaceutical firm that aims at developing life-altering medicines that target genetic diseases at their source.

QED Therapeutics – a subsidiary of BridgeBio Pharma Inc. is a leading biotechnology firm that aims at developing precision medicine for FGFR- related diseases. The company proposes to submit a new drug application with the U.S. F.D.A. for second and later stages cholangiocarcinoma in the year 2020.

 

Source Credits: https://bridgebio.com/news/bridgebio-pharmas-qed-therapeutics-announces-dosing-of-first-patients-in-phase-3-and-phase-2-clinical-trials-of-infigratinib-in-tumors-with-fgfr-genetic-alterations

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

By Mateen Dalal

Lo! Foods, a Bengaluru-based consumer goods startup has reportedly secured USD 1 million during its pre-series A funding round, which was led by Chona Family Office, the former promoters of the renowned Hamvor Ice Cream. Other investors that partici...

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

By Mateen Dalal

American Airlines and JetBlue had announced their partnership in July last year. According to the Justice Department, the deal may cause inflated fares at major traffic hubs. The United States Department of Justice (DOJ) has reportedly stepped ...

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

By Mateen Dalal

The two companies intend to introduce their custom-made sub-6GHz 5G chipsets by the end of 2021. UNISOC has managed to raise around USD 817.20 million for its new venture. Chinese electronics giants including Xiaomi Corp. and Guangdong Oppo Mob...